A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation.
Ejaculation
About this trial
This is an interventional treatment trial for Ejaculation focused on measuring dapoxetine, rapid ejaculation, premature ejaculation, ejaculation, sexual dysfunction, orgasmic disorder, sexual intercourse
Eligibility Criteria
Inclusion Criteria: Heterosexual male in a stable, monogamous, sexual relationship with a female partner for at least 6 months onset of orgasm and ejaculation occurs with minimal sexual stimulation before or shortly after penetration and before the person wishes it premature ejaculation (PE) in the majority of intercourse experiences in the 6 months before study initiation intravaginal latency ejaculatory time (IELT) of <=2 minutes in at least 3 out of 4 events participants with partners of child-bearing potential must consent to use a medically acceptable method of contraception throughout the entire study participant's partner must have a negative pregnancy test at time of screening. Exclusion Criteria: History of surgery or injury to the pelvis or spinal cord, chronic inflammation of the prostate or urethra taking medications that are contraindicated for participation in the study currently using other forms of therapy for treatment of PE (for example, behavioral therapy or medications applied locally) previously participated in a drug study involving dapoxetine or in another drug trial within the last month taken pimozide, astemizole, or monoamine oxidase inhibitors within 6 months of the start of the study.